MYCOF - Mydecine Announces API-Naming Structure of Four Lead Candidates and Prepares for Pre-IND

DENVER, April 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group™(CSE:MYCO)(OTC:MYCOF)(FSE: 0NFA)(“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada.

“Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers ...